Avadel Pharmaceuticals plc (NASDAQ: AVDL) is 47.68% higher on its value in year-to-date trading and has touched a low of $1.03 and a high of $10.75 in the current 52-week trading range. The AVDL stock was last observed hovering at around $9.83 in the last trading session, with the day’s gains setting it 1.32% off its average median price target of $14.00 for the next 12 months. It is also 38.06% off the consensus price target high of $18.00 offered by 5 analysts, but current levels are 20.36% higher than the price target low of $14.00 for the same period.
Currently trading at $11.15, the stock is 23.49% and 31.84% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.15 million and changing 13.43% at the moment leaves the stock 100.36% off its SMA200. AVDL registered 922.94% gain for a year compared to 6-month gain of 168.67%. The firm has a 50-day simple moving average (SMA 50) of $8.13 and a 200-day simple moving average (SMA200) of $6.93.
The stock witnessed a 18.62% loss in the last 1 month and extending the period to 3 months gives it a 73.68%, and is 18.37% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.91% over the week and 11.28% over the month.
Avadel Pharmaceuticals plc (AVDL) has around 50 employees, a market worth around $524.72M and $59.20M in sales. Profit margin for the company is -56.10%. Distance from 52-week low is 982.52% and 3.72% from its 52-week high. The company has generated returns on investments over the last 12 months (-23.20%).
Avadel Pharmaceuticals plc (AVDL) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Avadel Pharmaceuticals plc (AVDL) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.40, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Avadel Pharmaceuticals plc is expected to release its quarterly report on 05/06/2020 and quarterly earnings per share for the current quarter are estimated at -$0.24 with sales reaching $10.15M over the same period.The EPS is expected to grow by 65.30% this year, but quarterly earnings will post -29.90% year-over-year. Quarterly sales are estimated to shrink -26.80% in year-over-year returns.
Avadel Pharmaceuticals plc (AVDL) Top Institutional Holders
50 institutions hold shares in Avadel Pharmaceuticals plc (AVDL), with 4M shares held by insiders accounting for 8.62% while institutional investors hold 45.66% of the company’s shares. The shares outstanding are 47.06M, and float is at 35.64M with Short Float at 18.23%. Institutions hold 41.73% of the Float.
The top institutional shareholder in the company is Brandes Investment Partners L.P. with over 3.65 million shares valued at $27.57 million. The investor’s holdings represent 9.75% of the AVDL Shares outstanding. As of Dec 30, 2019, the second largest holder is RTW Investments LP with 3.4 million shares valued at $25.68 million to account for 9.08% of the shares outstanding. The other top investors are Brown Capital Management, Inc. which holds 1.83 million shares representing 4.89% and valued at over $13.82 million, while Acuta Capital Partners LLC holds 4.34% of the shares totaling 1.63 million with a market value of $12.27 million.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
A total of 0 insider transactions have happened at Avadel Pharmaceuticals plc (AVDL) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Hatten Sandra L. SEC filings show that Hatten Sandra L sold 3,072 shares of the company’s common stock on Dec 12 at a price of $7.23 per share for a total of $22211.0. Following the sale, the insider now owns 55765.0 shares.
Avadel Pharmaceuticals plc disclosed in a document filed with the SEC on Dec 04 that Ende Eric J (Director) bought a total of 10,000 shares of the company’s common stock. The trade occurred on Dec 04 and was made at $5.97 per share for $59700.0. Following the transaction, the insider now directly holds 47900.0 shares of the AVDL stock.
Still, SEC filings show that on Dec 03, Palczuk Linda (Director) acquired 7,500 shares at an average price of $5.91 for $44325.0. The insider now directly holds 35,400 shares of Avadel Pharmaceuticals plc (AVDL).
Avadel Pharmaceuticals plc (AVDL): Who are the competitors?
The company’s main competitors (and peers) include Eagle Pharmaceuticals Inc. (EGRX) that is trading -3.29% down over the past 12 months. Heron Therapeutics Inc. (HRTX) is -36.70% down on the 1-year trading charts. Short interest in the company’s stock has risen 39.23% from the last report on Mar 12, 2020 to stand at a total of 3.95 million short shares sold with a short interest ratio of 11.82.